DOCSLIB.ORG

Clinical Neuroscience Solutions, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Neuroscience Solutions, Inc JOHN MARK JOYCE, M.D. CNS HEALTHCARE OF JACKSONVILLE Affiliation Investigator Clinical Neuroscience Solutions, Inc. 5200 Belfort Road, Suite 420, Jacksonville, FL 32256 2003 - Present Clinical Trial Experience 2003-Present Principal Investigator on over 200 phase II – IV clinical and Interest trials in children, adults, and geriatrics. Sleep Disorders, Chronic Pain, Osteoarthritis, Smoking Cessation, Alcohol Dependence, Substance Use Disorders, Migraine, Alzheimer’s Disease, Rheumatologic Disorders, Skin Disorders, Women’s Health, Attention Deficit Hyperactivity Disorder, Autism, Mood Disorders, Obesity, Binge Eating Disorder, Bipolar Disorder, Dementia, Diabetes, Diabetic Peripheral Neuropathy, Diverticulitis, Fatigue, Female Sexual Arousal Disorder, Gambling, Anxiety Disorders, Gout, Hot Flashes, Hypertension, Irritable Bowel Syndrome, Mild Cognitive Impairment, Obsessive-Compulsive Disorder, Fibromyalgia, Oppositional Defiant Disorder, Panic Disorder, Post Traumatic Stress Disorder, Schizophrenia, Sexual Dysfunction, Social Phobia, Stuttering, Vulvar & Vaginal Atrophy, Chronic Idiopathic Constipation, Opioid Induced Constipation, Asthma, COPD, Flu Treatment, Down Syndrome, Post Herpetic Neuralgia and Hyperlipidemia Professional Training and 1988 -1989 Internal Medicine and Neurology Internship, Emory Experience University School of Medicine, Atlanta GA 1989 - 1992 Psychiatry Residency, Emory University School of Medicine, Atlanta, GA 1991-1992 Chief Resident, Department of Psychiatry, Grady Memorial Hospital, Atlanta, GA 1992-2000 Private Practice, Atlanta, GA 1992 – 1996 Consultant, Gwinnett/Rockdale/Newton Recover Center 1996 – 2000 Medical Director, Gwinnett/Rockdale/Newton Recovery Center 2001-2006 Director of Psychiatric Services, Duval County Pretrial Detention Center 2001- Present Private Practice, Jacksonville, FL CNS Healthcare Jacksonville - 5200 Belfort Road, Suite 420, Jacksonville, Florida 32256 Tel: (904) 281-5757 Fax: (904) 281-5758 Mobile (904) 654-6451 www.cnshealthcare.com/Jacksonville [email protected] Page 1 of 3 CNS Healthcare of Jacksonville Clinical Neuroscience Solutions, Inc. JOHN MARK JOYCE, M.D. CNS HEALTHCARE OF JACKSONVILLE Education 1980-1984 B.S., Birmingham Southern College Department of Psychology Birmingham, AL 1984-1988 M.D., University of Alabama School of Medicine Birmingham, AL License/ Accreditation Florida: No. ME 81135 Georgia: No. 032593 Drug Enforcement Administration: BJ7100833 (Florida) & BJ3162601 (Georgia) American Board of Psychiatry and Neurology Industry Contacts Industry contracts include: Abbott, Addrenex Pharma, Alder, Alkermes, Allergan, Allon Therapeutics, Arena, Array, AstraZeneca, Avanir, Avera, Bristol-Myers Squibb, Boehringer Ingelheim, Cephalon, Daiichi Sanko, DOV, Eli Lilly, Epix Pharmaceuticals, Euthymics, Forest, Furiex, GlaxoSmithKline, Indevus, Johnson & Johnson, Labopharm, Labrys, Lundbeck, Merck, McNeil, Myriad, Neurocrine, New River Pharmaceuticals, Novartis, NovoNordisk, Ono Pharma USA, Organon, Otsuka, Pfizer, Purdue, Rexhan, Sanofi, Sepracor, Shionogi, Shire, Solvay, Somaxon, Sunovion, Supernus, Synergy, Takeda, Targacept, TransTech, Vanda and Wyeth, AssureRx, Astellas, Dr. Reddy’s, Edgemont,IronShore, Nestle Health Science, Palatin, Noven, Regeneron, Tal Medical, Genomind, Medgenics, Roche, Axsome, Neuralstem, Colucid, Alcobra, Acadia, NLS Pharma. Original Articles McCallum, D.M., McCallum, R., Gurwitch, R.H., & Joyce, J.M. (1986). Assessing Perceptions of Dental Health Behaviors. Clinical Preventative Dentistry, 8, 27-30. Hughes, T.A., Moore, M.A, Joyce, J.M., Go, R.C.P, Segrest, J.P. & Blackwell, T. (1992). Sexual Differences in Lipoprotein Composition in Dyslipidemic Hypertension with Premature Atherosclerosis: Deficiency of HDL-l and HDL-M “A-I Alone” Particle. Journal of Laboratory and Clinical Medicine, 119(1). Weisler, R., Joyce, J.M, McGill, L., Lazarus, A., Szamosi, J., Eriksson, H. (2009). Extended Release Quetiapine Fumarate Monotherapy for Major Depressive Disorder: Results of a Double-Blind, Randomized, Placebo- Controlled Study. CNS Spectr. 2009; 14(6):299-313. El-Khalili N., Joyce M., Atkinson S., Buynak R. J., Datto C., Lindgren P., CNS Healthcare Jacksonville - 5200 Belfort Road, Suite 420, Jacksonville, Florida 32256 Tel: (904) 281-5757 Fax: (904) 281-5758 Mobile (904) 654-6451 www.cnshealthcare.com/Jacksonville [email protected] Page 2 of 3 CNS Healthcare of Jacksonville Clinical Neuroscience Solutions, Inc. JOHN MARK JOYCE, M.D. CNS HEALTHCARE OF JACKSONVILLE Eriksson H., Extended –Release Quetiapine Fumarate (Quetiapine XR) as Adjunctive Therapy in Major Depressive Disorder (MDD) in Patients with an Inadequate Response to Ongoing Antidepressant Treatment: A Multicentre, Randomized, Double-Blind, Placebo Controlled Study. International Journal of Neuropsychopharmacology, Vol 23:1-16, February 2010. Abstracts Joyce, M., Khan, A., Atkinson, S., Eggens, I., Baldytcheva, I., Brecher, M., (2007). Efficacy and Safety of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Generalized Anxiety Disorder (GAD). American Psychiatric Association Convention. Khan, A., Joyce, M., Atkinson, S., Eggens, I., Baldytcheva, I., Brecher, M. (2007). Efficacy and Safety of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Generalized Anxiety Disorder (GAD). Anxiety Disorders Association of America, 28th Annual Conference. El-Khalili, N., Joyce, M., Atkinson, S., Buynak, R., Datto, C., Lindgren, P., Eriksson, H., Brecher, M., (2007). Adjunctive Extended Release Quetiapine Fumarate (Quetiapine XR) in Patients with Major Depressive Disorder and Inadequate Antidepressant Response. American Psychiatric Association Convention. Weisler, R., Joyce, M., McGill, L., Lazarus, A., Schollin, M., Brecher, M., (2007). Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy for Major Depressive Disorder (MDD): A Double-Blind Placebo Controlled Study. Hughes, T.A., Moore, M.A., Joyce, J.M., Go, R.C.P, Segrest, J.P., & Blackwell, T. (1998). Family with Hypertiglyceridemia and Premature Atherosclerosis: “Light ApoA-1” Deficiency. Atherosclerosis, 8, 578a. CNS Healthcare Jacksonville - 5200 Belfort Road, Suite 420, Jacksonville, Florida 32256 Tel: (904) 281-5757 Fax: (904) 281-5758 Mobile (904) 654-6451 www.cnshealthcare.com/Jacksonville [email protected] Page 3 of 3 CNS Healthcare of Jacksonville Clinical Neuroscience Solutions, Inc. .
Load more

Recommended publications
  • Welcome to the New Open Access Neurosci
    Editorial Welcome to the New Open Access NeuroSci Lucilla Parnetti 1,* , Jonathon Reay 2, Giuseppina Martella 3 , Rosario Francesco Donato 4 , Maurizio Memo 5, Ruth Morona 6, Frank Schubert 7 and Ana Adan 8,9 1 Centro Disturbi della Memoria, Laboratorio di Neurochimica Clinica, Clinica Neurologica, Università di Perugia, 06132 Perugia, Italy 2 Department of Psychology, Teesside University, Victoria, Victoria Rd, Middlesbrough TS3 6DR, UK; [email protected] 3 Laboratory of Neurophysiology and Plasticity, Fondazione Santa Lucia, and University of Rome Tor Vergata, 00143 Rome, Italy; [email protected] 4 Department of Experimental Medicine, University of Perugia, 06132 Perugia, Italy; [email protected] 5 Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy; [email protected] 6 Department of Cell Biology, School of Biology, University Complutense of Madrid, Av. Jose Antonio Novais 12, 28040 Madrid, Spain; [email protected] 7 School of Biological Sciences, University of Portsmouth, Hampshire PO1 2DY, UK; [email protected] 8 Department of Clinical Psychology and Psychobiology, University of Barcelona, 08035 Barcelona, Spain; [email protected] 9 Institute of Neurosciences, University of Barcelona, 08035 Barcelona, Spain * Correspondence: [email protected] Received: 6 August 2020; Accepted: 17 August 2020; Published: 3 September 2020 Message from Editor-in-Chief: Prof. Dr. Lucilla Parnetti With sincere satisfaction and pride, I present to you the new journal, NeuroSci, for which I am pleased to serve as editor-in-chief. To date, the world of neurology has been rapidly advancing, NeuroSci is a cross-disciplinary, open-access journal that offers an opportunity for presentation of novel data in the field of neurology and covers a broad spectrum of areas including neuroanatomy, neurophysiology, neuropharmacology, clinical research and clinical trials, molecular and cellular neuroscience, neuropsychology, cognitive and behavioral neuroscience, and computational neuroscience.
    [Show full text]
  • Course Syllabus Psychology 267 Clinical Neuroscience Larry Wichlinski Spring Term, 2016
    1 Course Syllabus Psychology 267 Clinical Neuroscience Larry Wichlinski Spring Term, 2016 Office: Olin 123, Ext. 4377, e-mail: LWICHLIN Office Hours: Tuesday 1-3 p.m. Wed. 4a; Fri. 4a and by appointment Required Books: Pistorius, M. (2013). Ghost Boy. Nashville: Nelson Books. Introduction Welcome to Clinical Neuroscience! In this course we will examine the biological dimensions of disorders of the mind and brain. The goal is to gain a better understanding of the role that biological factors play when our brains and minds go awry. The format of this class will be a combination of lecture and discussion. The class is organized by brain disorder, but some themes recur throughout the course, as you will see. The bulk of the reading assignments are journal articles, most of them quite recently published. In addition, we will read selective websites and a contemporary book, Ghost Boy. Please have the assigned readings done by the time you get to class, if at all possible. Also, please have some form of the articles available during class time. Most of the journal articles are available via the Web of Knowledge through the library’s website. The few that are not available will be put on e-reserve for this course. I’ll let you know which articles fall in this category. I may add readings and/or substitute readings as this course unfolds. I will do my best to let you know of any changes in a timely fashion. Exams & Quizzes There will be two quizzes and two exams in this course. Quizzes will consist of multiple choice and short answer questions.
    [Show full text]
  • 178S ASMS Directory of Members DAVID AASERUD the Lubrizol
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector 178S ASMS Directory of Members DAVID AASERUD SUZANNE ACKLOO WILLIAM ADAMS The Lubrizol Corporation MDS Sciex Philip Morris USA 29400 Lakeland Blvd. 71 Four Valley Drive RD&E/OC-T3W Wickliffe, OH 44092 Concord, ON L4K 4V8 Canada 615 Maury Street Tel: 440 347 4776 Tel: 905 660 9005 Richmond, VA 23224 [email protected] [email protected] Tel: 804 274 2093 [email protected] SUSAN ABBATIELLO EUREKA ACOLATSE University of Florida 7237 Causeway Dr. #3B GARY E. ADAMSON Department of Chemistry Indianapolis, IN 46214 Merck and Co. PO Box 117200 Tel: 317 433 4016 Merch Research Laboratories Gainesville, FL 32611 [email protected] P.O. Box 4 Tel: 352 392 0536 West Point, PA 19486 [email protected] CHRIS ADAMS Tel: 215 652 1174 Uppsala University [email protected] LARRY ABBEY Biological & Medical Mass Spec Waters Corporation Box 583, BMC JULIE ADAMSON 4026 Oak Crest Drive Uppsala, SE-751 23 Sweden University of Michigan Tucker, GA 30084 Tel: 46 18 471 5729 930 N. University Tel: 770 414 5089 [email protected] Ann Arbor, MI 48109-1055 [email protected] Tel: 734-763-6535 GREG ADAMS [email protected] FRANK S. ABBOTT Diosynth Biotechnology University of British Columbia 3000 Weston Parkway TOM ADDISON Faculty of Pharmaceutical Science Cary, NC 27513 Covance-11 2146 East Mall Tel: 919 388 5690 6002/11 Vancouver, BC V6T 1Z3 Canada [email protected] 3301 Kinsman Boulevard Tel: 604 822 2566 Madison, WI 53704-2523 [email protected] LUKE ADAMS Tel: 608 242 2639 University of Washington, Chemistry [email protected] FADI ABDI Box 351700 Applied Biosystems Seattle, WA 98195 TERRI ADDONA 500 Old Connecticut Path Tel: 206 543 7656 Broad Instritute Framingham, MA 01702 [email protected] 320 Charles Street Tel: 508 383 7921 Cambridge, MA 02141 [email protected] NIGEL G.
    [Show full text]
  • Social Cognitive Neuroscience
    Chapter 5 Social Cognitive Neuroscience M ATTHEW D . L IEBERMAN Who we are as humans has a lot to do with what happens have become leaders in the field, despite few having pub- between our ears. What happens between our ears has a lot lished social cognitive neuroscience findings at that point. to do with the social world we traverse, engage, and react There were introductory talks on social cognition and cog- to. The former has been the province of neuroscience and nitive neuroscience by Neil Macrae and Jonathan Cohen, the latter the province of social psychology for nearly a respectively, along with symposia on stereotyping (William century. Recently, scientists have begun to study the social Cunningham, Jennifer Eberhardt, Matthew Lieberman, mind by literally looking between the ears using the tools and Wendy Mendes), self - control (Todd Heatherton, Kevin of neuroscience. Social cognitive neuroscience uses the tools Ochsner, and Cary Savage), emotion (Ralph Adolphs, of neuroscience to study the mental mechanisms that cre- Turhan Canli, Elizabeth Phelps, and Stephanie Preston), ate, frame, regulate, and respond to our experience of the imitation and social relations (Alan Fiske, Marco Iacoboni, social world. On its worst days, social cognitive neurosci- David Perrett, and Andrew Whiten), and theory of mind ence is phrenological, cataloguing countless brain regions (Chris Ashwin, Josep Call, Vittorio Gallese, and Kevin involved in the vast array of social processes. On its best McCabe). If this meeting represented the first time that all days, social cognitive neuroscience enhances our under- of the ingredients of social cognitive neuroscience were standing of the social mind as well as any other method.
    [Show full text]
  • Methodological Dimensions of Transcranial Brain Stimulation with the Electrical Current in Human
    Basic and Clinical August 2013, Volume 4, Number 3 Review Paper: Methodological Dimensions of Transcranial Brain Stimulation with the Electrical Current in Human Maryam Rostami1, 4, Mehrshad Golesorkhi1, 2, 5, Hamed Ekhtiari1, 2, 3* 1. Translational Neuroscience Program, Institute for Cognitive Science Studies, Tehran, Iran. 2. Neuroimaging and Analysis Group, Research Center for Molecular and Cellular Imaging, Tehran University for Medical Sciences, Tehran, Iran. 3. Iranian National Center for Addiction Studies, Tehran University for Medical Sciences, Tehran, Iran. 4. Department of Biomedical Engineering, Amirkabir University of Technology (Tehran Polytechnic), Tehran, Iran. 5. Department of Computer Science, School of Mathematics, Statistics and Computer Science, University of Tehran, Tehran, Iran. Article info: A B S T R A C T Received: 16 October 2012 Transcranial current stimulation (TCS) is a neuromodulation method in which the patient is First Revision: 10 February 2013 exposed to a mild electric current (direct or alternating) at 1-2 mA, resulting in an increase Accepted: 20 May 2013 or a decrease in the brain excitability. This modification in neural activities can be used as a method for functional human brain mapping with causal inferences. This method might Key Words: also facilitate the treatments of many neuropsychiatric disorders based on its inexpensive, Transcranial Electrical Stimulation (tES), simple, safe, noninvasive, painless, semi-focal excitatory and inhibitory effects. Given this, Transcranial Direct Current a comparison amongst different brain stimulation modalities has been made to determine Stimulation (tDCS), the potential advantages of the TCS method. In addition, considerable methodological Transcranial Alternating Current details on using TCS in basic and clinical neuroscience studies in human subjects have Stimulation (tACS), been introduced.
    [Show full text]
  • Feasibility of Using Cranial Electrotherapy Stimulation for Pain in Persons with Parkinson’S Disease
    SAGE-Hindawi Access to Research Parkinson’s Disease Volume 2010, Article ID 569154, 8 pages doi:10.4061/2010/569154 Research Article Feasibility of Using Cranial Electrotherapy Stimulation for Pain in Persons with Parkinson’s Disease Diana H. Rintala,1, 2 Gabriel Tan,1, 2, 3 Pamela Willson,1, 4, 5 Mon S. Bryant,1, 2 andEugeneC.H.Lai1, 4, 5 1 Research Service, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA 2 Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX 77030, USA 3 Department of Anesthesiology, Baylor College of Medicine, Houston, TX 77030, USA 4 Parkinson’s Disease Research, Education and Clinical Center, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA 5 Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA Correspondence should be addressed to Diana H. Rintala, [email protected] Received 23 September 2009; Revised 11 January 2010; Accepted 28 February 2010 Academic Editor: Eng King Tan Copyright © 2010 Diana H. Rintala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objectives. To assess the feasibility of treating musculoskeletal pain in the lower back and/or lower extremities in persons with Parkinson’s disease (PD) with cranial electrotherapy stimulation (CES). Design. Randomized, controlled, double-blind trial. Setting. Veterans Affairs Medical Center, Community. Participants. Nineteen persons with PD and pain in the lower back and/or lower extremities. Thirteen provided daily pain rating data.
    [Show full text]
  • Brain Imaging Technologies
    Updated July 2019 By Carolyn H. Asbury, Ph.D., Dana Foundation Senior Consultant, and John A. Detre, M.D., Professor of Neurology and Radiology, University of Pennsylvania With appreciation to Ulrich von Andrian, M.D., Ph.D., and Michael L. Dustin, Ph.D., for their expert guidance on cellular and molecular imaging in the initial version; to Dana Grantee Investigators for their contributions to this update, and to Celina Sooksatan for monograph preparation. Cover image by Tamily Weissman; Livet et al., Nature 2017 . Table of Contents Section I: Introduction to Clinical and Research Uses..............................................................................................1 • Imaging’s Evolution Using Early Structural Imaging Techniques: X-ray, Angiography, Computer Assisted Tomography and Ultrasound..............................................2 • Magnetic Resonance Imaging.............................................................................................................4 • Physiological and Molecular Imaging: Positron Emission Tomography and Single Photon Emission Computed Tomography...................6 • Functional MRI.....................................................................................................................................7 • Resting-State Functional Connectivity MRI.........................................................................................8 • Arterial Spin Labeled Perfusion MRI...................................................................................................8
    [Show full text]
  • Art Therapy and the Malnourished Brain: the Development of the Nourishment Framework
    Art Therapy and the Malnourished Brain: The Development of the Nourishment Framework Article submission for Art Therapy: Journal of the American Art Therapy Association ARTTHERAPY-D-19-00021 Eileen Misluk-Gervase INDIANAPOLIS, INDIANA USA Editor’s Note: Eileen Misluk-Gervase, ATR-BC, LPC is an Assistant Professor, Director and Internship Coordinator for the Art Therapy Program at Indiana University Purdue University Indianapolis with Herron School of Art and Design, Indianapolis, Indiana. Correspondence can be directed to the author at [email protected] ________________________________ This is the author’s manuscript of the article published in final edited form as: Misluk-Gervase, E. (2020). Art Therapy and the Malnourished Brain: The Development of the Nourishment Framework. Art Therapy, 1-11. https://doi.org/10.1080/07421656.2020.1739599 Art Therapy and the Malnourished Brain: The Development of the Nourishment Framework Article submission for Art Therapy: Journal of the American Art Therapy Association ARTTHERAPY-D-19-00021 Word Count: 5,276 (6 figures, 1 table) Abstract Art therapy can be particularly successful in addressing the specific needs of individuals struggling with anorexia nervosa (AN) through the use of the creative process. This article provides an understanding of the effect of malnourishment on the brain for individuals with AN and discusses how their unique needs can be met through the application of the Nourishment Framework. The Nourishment Framework is a structured treatment approach that utilizes the individual components of the Expressive Therapies Continuum (ETC) to address specific clinical needs for those struggling with AN. A case study documents the application of the Nourishment Framework while highlighting the directives and materials used to meet client goals.
    [Show full text]
  • The Road Ahead in Clinical Network Neuroscience
    REVIEW The road ahead in clinical network neuroscience ∗ ∗ Linda Douw1, , Edwin van Dellen2,3, , Alida A. Gouw4,5, Alessandra Griffa6, Willem de Haan4,5, Martijn van den Heuvel6,7, Arjan Hillebrand4, Piet Van Mieghem8, Ida A. Nissen4, Willem M. Otte9,10, Yael D. Reijmer11, Menno M. Schoonheim1, Mario Senden12,13, Elisabeth C. W. van Straaten4, Betty M. Tijms5, Prejaas Tewarie4, and Cornelis J. Stam4 1Department of Anatomy and Neuroscience, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands 2Department of Psychiatry, Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands 3Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Melbourne, Australia 4Department of Neurology, Clinical Neurophysiology and MEG Center, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands an open access journal 5Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands 6Connectome Lab, Department of Neuroscience, section Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands 7Department of Clinical Genetics, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands 8Faculty of Electrical Engineering, Mathematics and Computer Science, Delft University of Technology, Delft, The Netherlands 9Biomedical
    [Show full text]
  • Oral Presentation Disclosures
    Oral Presentation Disclosures Adler, Lenard – Alcobra Pharma, APSARD/Pond Foundation, Major League Baseball, Major League Baseball Players Association, National Football League, New York University School of Medicine, Novartis Bioventures, Shire Pharmaceuticals, Sunovion, SUNY Upstate, Theravance, US Department of Veterans Affairs Cooperative Studies Program Anton, Raymond – Abbvie, Alkermes, Eli Lilly, Ethypharm, Lundbeck, Pfizer, Sunpharma Baker, Ross – Otsuka Pharmaceutical Development & Commercialization, Inc. Baldwin, David – Lundbeck Beaver, Jessica – Targacept, Inc. Bencherif, Merouane – Targacept, Inc. Bertolino, Alessandro – F. Hoffmann-La Roche, Ltd. Bradshaw, Mark – Euthymics Bioscience, Neurovance, Inc. Burdick, Katherine – Dainippon Sumitomo Pharma Bymaster, Frank – Euthymics Bioscience, Neurovance, Inc. Calabrese, Joseph – Sunovion, Teva (Cephalon) Cantillon, Marc – Forest, Kyowa, Lilly, Merck, Pfizer, Reviva Caroff, Stanley – Sunovion Chen, Yinzhong – Takeda Development Center Americas, Inc. Chengappa, Roy – Pfizer, Inc. Childress, Ann – Abbott Laboratories, Bristol Myer Squibb, GlaxoSmithKline, Ironshore, Janssen (Ortho-McNeil), Johnson & Johnson PRD, Lilly, Neos Therapeutics, Neurovance Inc., NextWave, Novartis, Noven, Otsuka, Pfizer, Rhodes, Sepracor, Shionogi, Shire, Somerset, Sunovion, Theravance Christine, Mazzucco – Janssen Cohen, Lee – Astra-Zeneca Pharmaceuticals, Bristol-Myers Squibb, Cephalon, Inc., GlaxoSmithKline, National Institute of Mental Health, National Institute on Aging, Noven Pharmaceuticals, Ortho-McNeil
    [Show full text]
  • Beyond Borders Global Biotechnology Report 2009 “It Is Different This Time Because This Crisis Is Deep-Rooted, Systemic and Persistent
    For media use only Under embargo until 5:01 UK time on 5 May 2009 Beyond borders Global biotechnology report 2009 “It is different this time because this crisis is deep-rooted, systemic and persistent. But, in spite of that, the industry has been here before, in that biotech companies have overcome seemingly insurmountable challenges in the past, bucking trends and defying odds.“ Glen T. Giovannetti and Gautam Jaggi, Ernst & Young Global Biotechnology Center To our clients and friends As the shockwaves from the global financial crisis rippled across the emphasizes the need for partnering models that allow companies world economy in late 2008 and 2009, they left little untouched. the flexibility to evolve, while Samantha Du of Hutchison The reverberations leveled long-standing institutions, triggered MediPharma discusses how China can offer firms advantages that unprecedented policy responses and revealed new risks. For the address weaknesses in the Western business model. biotechnology industry, the impact of these turbulent times has But turbulent times can make the unimaginable possible, and deepened the divide between the sector’s haves and have-nots. sweeping disruptions have often redrawn maps, changed playing Many small-cap companies are scrambling to raise capital and fields and altered rules and regimes. In “Beyond business as contain spending, while a select few continue to attract favorable usual?” — our Global introduction article — we present four valuations from investors and strategic partners. paradigm-shifting trends that have the potential to reshape the A number of this year’s articles focus on the acute challenges healthcare landscape and create new opportunities: high-quality created by the funding crisis.
    [Show full text]
  • A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder
    Neuropsychopharmacology (2017) 42, 2567–2574 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder *,1,2 3,4 5 6 3 Sanjay J Mathew , Ralitza Gueorguieva , Cynthia Brandt , Maurizio Fava and Gerard Sanacora 1Mental Health Care Line, Michael E. DeBakey VA Medical Center, Houston, TX, USA; 2Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA; 3Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; 4 5 Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA; Departments of Emergency Medicine and Anesthesiology, Yale 6 University School of Medicine, New Haven, CT, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA Riluzole is a glutamate-modulating agent with neuroprotective properties approved for use in amyotrophic lateral sclerosis. The efficacy and safety of riluzole vs placebo as an adjunct to antidepressant medication in outpatients with major depressive disorder (MDD) was examined in a 3-site, 8-week, randomized, double-blind, placebo-controlled, fixed-dose trial using a sequential parallel comparison design = comprised of two phases of 4 weeks. Patients with MDD in a current major depressive episode (N 104) with an inadequate response to either a prospective or a historical trial of an antidepressant medication were randomized in a 2 : 3 : 3 ratio to the treatment sequences of riluzole/riluzole, placebo/placebo, and placebo/riluzole, respectively. The primary outcome was change in depression severity, as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS).
    [Show full text]